Arrowhead Pharmaceuticals has surged over 240% in six months, driven by major partnerships and its RNAi drug pipeline. Recent catalysts include a $200M Novartis deal, $300M from Sarepta, and the first ...
Arrowhead Pharmaceuticals (ARWR) has surged over 240% in 2025, driven by major partnership deals and its first commercial approval for Redemplo. ARWR's valuation is buoyed by $200M upfront from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results